Update on the timeline for Vifor Pharma tender offer

Rhea-AI Summary

CSL Limited (ASX: CSL; USOTC: CSLLY) announced an update on its acquisition of Vifor Pharma AG, originally expected to close by June 2022. While some antitrust approvals have been received, others are still pending. CSL reassured shareholders that such delays are common and that they are collaborating with remaining authorities for timely resolution. A precise closing date will be communicated once all regulatory approvals are confirmed, and CSL remains confident in finalizing the acquisition.

Positive

• CSL has received some antitrust approvals for the Vifor Pharma acquisition.
• CSL is actively working with authorities to expedite the approval process.

Negative

• Delays in obtaining regulatory approvals could postpone the acquisition timeline.
• Uncertainties around the remaining approvals may affect investor confidence.

ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Regulatory News:

CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that it expected to be in a position to close the acquisition of Vifor Pharma AG by June 2022. While some antitrust authorities have approved the transaction, some approvals are still outstanding.

Delays in the regulatory approval process are not unusual. CSL and Vifor Pharma are continuing to work closely with the respective remaining competition authorities in their review of the tender offer. CSL and Vifor Pharma expect to provide an update to shareholders and investors as soon as there is more clarity on the timeline.

An exact closing and settlement date will be communicated once all regulatory approvals have been received. CSL remains confident of completing its acquisition of Vifor Pharma AG.

About Vifor Pharma Group

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency and nephrology. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions across iron, dialysis, nephrology and rare conditions. Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and includes the companies: Vifor Pharma, Sanifit Therapeutics, and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit viforpharma.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005641/en/

Contact and further information:

Nathalie Ponnier

Global Head Corporate Communications

+41 79 957 96 73

media@viforpharma.com

Source: Vifor Pharma Group

FAQ

What is the status of CSL Limited's acquisition of Vifor Pharma AG?

CSL Limited announced that while some antitrust authorities have approved the acquisition, others are still pending.

When did CSL Limited expect to close the acquisition of Vifor Pharma?

CSL originally expected to close the acquisition by June 2022.

What factors are causing delays in CSL Limited's Vifor Pharma acquisition?

Delays are due to pending regulatory approvals from some antitrust authorities.

What is the stock symbol for CSL Limited?

The stock symbol for CSL Limited is CSL on the ASX and CSLLY on the USOTC.

How is CSL Limited addressing the delay in the Vifor Pharma acquisition?

CSL is working closely with competition authorities to expedite the approval process.